Management and operative team
Stefan Johansson, CEO
Stefan Johansson, CEO, is a Consultant Neonatologist and Associate Professor, and holds a PhD in epidemiology and biostatistics at Karolinska Institutet. In addition to be a social entrepreneur, being founder of 99nicu.org and ebneo.org, he has vast knowledge in research design and works in several large-scale projects. With his methodological expertise, Stefan Johansson has published on a large variety of research topics, including very preterm birth, maternal obesity, patent ductus arteriosus, neonatal jaundice, Down syndrome and birth asphyxia.
Philipp Novak, COO, holds a doctorate in veterinary medicine and an MSc in pharmaceutical medicine, and has more than 14 years of industry experience, involving global roles in Research & Development and Innovation. Philipp Novak is also CEO and founder of orphanix GmbH, a development firm for medical treatments of rare and neglected diseases.
Natasha Olsson, Marketing Manager, holds a BSc in Business and Economics from Stockholm School of Economics. She has previously worked as a Project Manager within health care policy research and with marketing in the pharmaceutical industry. She has a broad international exposure, e.g., from studying in France and the Democratic Republic of Congo.
Vera Westin, Customer Support Manager, is dietitian and was employed at the Karolinska University Hospital between 1980 and 2018. She holds a PhD in neonatal nutrition at Karolinska Institutet. During the last two decades of her professional career, the clinical focus was on preterm infants’ nutrition and growth. As lead dietitian she had an important role regarding mind setting/know how of colleagues working at neonatal units locally as well as nationally.
Frank Alkenbrecher, European Sales Manager, has a MBA degree from the University of North Carolina and a MA degree from the University of Economics, Vienna, Austria. He has been working in the pharmaceutical industry for 28 years in the USA, France and Germany and was General Manager for several companies in the specialty field. He also had various Sales & Marketing positions with large pharmaceutical companies like Eli Lilly, Biogen and Bayer. Most recently, Frank was the head of the German affiliate of Zambon GmbH, a family-oriented pharmaceutical business based in Italy.
Paul Bellas has 32 years experience in pharmaceutical sales & marketing management. Following 13 successful years within the `blue chip` pharmaceutical industry, he has been working exclusively with orphan drugs, initially as International Marketing Director for Swedish Orphan International, followed by 12.5 years as General Manager of Orphan Europe (latterly Recordati Rare Diseases).
Vesa Loponen, Business Consultant in Finland, has extensive international experience in business management. He has worked almost four decades in marketing, sales and general management for both national and international pharmaceutical companies. Apart from his roles as Managing Director and line-manager, he has been active within health policy; e.g. as a member of the Board of Directors for Pharma Industry Finland (PIF) for 15 years. Vesa has also chaired the boards of Pharmaceutical Information Centre and pharmaceutical injuries insurance company.
Scientific Advisory Board
Janet Berrington is a consultant neonatal paediatrician and senior lecturer in Newcastle, UK. Her MD research was on neonatal immunology and she has ongoing research including clinical and translational elements. Janet Berrington is manager of the Great North Neonatal Biobank, a co-app in the EME funded mechanistic microbiomic and metabolomic study (MAGPIE, Mechanisms Affecting the Gut of Preterm Infants in Enteral feeding trials), and a member of the UK Neonatal Nutrition Network.
Francesco Cardona is a Consultant Neonatologist at the Medical University Vienna, Austria. He has a Masters Degree in Epidemiology. His previous research was at the Department of Clinical Pharmacology conducting interventional studies. Currently he is doing research on the Austrian birth registry. Francesco Cardona is also an administrator of the 99nicu.org community, project-leading the annual conference Future of Neonatal Care, AKA as the #99nicuMeetup.
Nicholas Embleton is a Consultant Neonatologist (appointed 2003) and Honorary Reader at Newcastle University, UK. His MD research was on protein requirements in preterm infants (awarded 2002). Since then he has developed a wide research portfolio including large studies funded by the NIHR. Nicholas Embleton is a member of the Committee of Nutrition, ESPGHAN. He also has extensive experience of qualitative studies with parents of preterm infants who did not survive. His research group website is www.neonatalresearch.net.
Per Torp Sangild
Per Torp Sangild is a Professor in Comparative Pediatrics and Nutrition at University of Copenhagen, Denmark and holds part-time appointments at Copenhagen and Odense University Hospitals. His degrees are PhD (1990), DVSc (1996) and DMSc (2010), all from University of Copenhagen. Research focus is on clinical nutrition and developmental gastroenterology with long experience in using animal (piglet) models for infants, particularly preterm infants. He is leading an international research network, NEOMUNE/NEOCOL, investigating milk and microbiota effects on immunity, gut and brain development (Danish Research Council, 2013-2021, www.neomune.ku.dk).
Marijn J. Vermeulen
Marijn J. Vermeulen is a Consultant Neonatologist, at Erasmus University Medical Center in The Netherlands, since 2008. Her clinical focus is on nutrition and growth after preterm birth. She is actively involved in the national neonatal parent advocacy organisation. As a senior researcher and clinical epidemiologist, she runs clinical studies (mainly in premature infants) and population based studies (embedded in Generation R and Generation R Next), on fetal and neonatal growth and the role of nutrition (including breast feeding, iron status) and circadian rhythm.
Frank Jochum is a paediatrician specialised in neonatology, paediatric intensive medicine, and paediatric clinical nutrition. After being the medical director of the Ev. Waldkrankenhaus Spandau in Berlin 2008-2014, he is now the Head of its Department of Paediatrics. Frank Jochum has several board and advisor appointments, including the “Vereinigung leitender Kinderärzte und Kinderchirurgen Deutschlands“ (VLKKD) and the German Hospital Federation (DKG). He is also author on numerous national and international publications in medical journals and books.
Board of Directors
Ann-Charlotte Beckman has extensive experience from marketing and sales in the European life science industry. She has over 15 years of experience in entrepreneurship and board work in owner-led companies and over 5 years of experience of being a business angel and external member of start-ups and scale-up companies in life science and healthtech. Ann-Charlotte was previously CEO at Netdoktor.se and has a background as a nurse.
Stefan Johansson (chairman)
Stefan Johansson, also CEO, is a Consultant Neonatologist and Associate Professor, and holds a PhD in epidemiology and biostatistics at Karolinska Institutet. In addition to be a social entrepreneur, being founder of 99nicu.org and ebneo.org, he has vast knowledge in research design and works in several large-scale projects. With his methodological expertise, Stefan Johansson has published on a large variety of research topics, including very preterm birth, maternal obesity, patent ductus arteriosus, neonatal jaundice, Down syndrome and birth asphyxia.
Kristina Magnusson Borg
Kristina Magnusson Borg has worked more than 35 years within the pharmaceutical and probiotic industries. Her experience ranges from basic and clinical research, business development to marketing & sales in senior and strategic positions on a global market. Kristina holds a Ph Licentiate degree in Medical Science, Karolinska Institute, as well as an Executive MBA.
Philipp Novak, also COO, holds a doctorate in veterinary medicine and an MSc in pharmaceutical medicine, and has more than 14 years of industry experience, involving global roles in Research & Development and Innovation. Philipp Novak is also CEO and founder of orphanix GmbH, a development firm for medical treatments of rare and neglected diseases.
Jens Sandström has a broad commercial and industrial background with many years in leading positions with emphasis on strategy development and implementation, investment assessments, leadership and change management, sales, product management and marketing. Jens has a background in operational roles within the life science industry and in management consulting.
Staffan Thunell has a long background in entrepreneurship within the life science industry. He has 15 years of experience from positions as Founder, Chairman, CEO and CFO within medical affairs consulting and small pharma. Previously, Staffan had executive positions in marketing and portfolio development positions in big pharma and specialty pharma companies.
Gustav Johansson holds a Bsc of business and economics, focused on accounting and finance, from Stockholm School of Economics. His analytic experience includes internships at Goldman Sachs (London office) and Altor (Stockholm office).
Bernd Kuntscher has a BSc in Business Administration and Economics from the Stockholm School of Economics. He has 28 years of experience in marketing and sales, market research and general management from the pharmaceutical and medical device industry. Bernd Kuntscher has worked at big pharmaceutical companies such as AstraZeneca and small, very specialised, companies such as Recordati Rare Diseases (previously Orphan Europe) where he is working now as General Manager for the Nordics & Baltics. He has experience from many different therapeutic areas, incuding rare metabolic diseases.
Mårten Österlund has a PhD from Uppsala University and post doctorate studies at the Pasteur Institute in Paris, France. He spent his working years in various leading positions at a number of pharmaceutical companies such as Karo Bio, Affibody and Meda. With extensive knowledge from the pharmaceutical market and having participated in research and clinical development of pharmaceuticals and documented knowledge in successful launches of innovative products. In 2018 Mårten Österlund founded Pharma Way AB.